Asterias Biotherapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
6
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 23, 2026The maintenance fee for Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells (US 9,062,289) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 2 fees due Jan 7 to 9, 2027 · next Jan 7
- 1 fee due Sep 5, 2027The maintenance fee for Oligodendrocyte Progenitor Cell Compositions (US 11,920,155) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Aug 25 US 12,716,054 Oligodendrocyte Progenitor Cell Compositions
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,153 | Differentiation and enrichment of islet-like cells from human pluripotent stem cells In force · USPTO record | In force | USPTO record | |
| US 9,062,289 | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells In force · USPTO record | In force | USPTO record | |
| US 7,897,389 | Direct differentiation method for making cardiomyocytes from human embryonic stem cells In force · USPTO record | In force | USPTO record | |
| US 10,344,262 | Differentiation of primate pluripotent stem cells to hematopoietic lineage cells In force · USPTO record | In force | USPTO record | |
| US 8,093,049 | Differentiation of primate pluripotent stem cells to hematopoietic lineage cells In force · USPTO record | In force | USPTO record | |
| US 9,074,181 | Suspension culture of human embryonic stem cells In force · USPTO record | In force | USPTO record | |
| US 10,286,009 | Pluripotent Stem Cell-Derived Oligodendrocyte Progenitor Cells for the Treatment of Spinal Cord Injury In force · High confidence | In force | High confidence | |
| US 11,123,374 | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury In force · USPTO record | In force | USPTO record | |
| US 12,716,054 | Oligodendrocyte Progenitor Cell Compositions In force · High confidence | In force | High confidence | |
| US 11,920,155 | Oligodendrocyte Progenitor Cell Compositions In force · High confidence | In force | High confidence |
Also on record, not counted in the 12: 26 lapsed for an unpaid fee · 36 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 14 no status recorded